Literature DB >> 25124779

First do no harm: infectious deaths in pediatric ALL.

Karen R Rabin1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25124779      PMCID： PMC4133499          DOI： 10.1182/blood-2014-06-581603

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.

Authors:  Kelly W Maloney; William L Carroll; Andrew J Carroll; Meenakshi Devidas; Michael J Borowitz; Paul L Martin; Jeanette Pullen; James A Whitlock; Cheryl L Willman; Naomi J Winick; Bruce M Camitta; Stephen P Hunger
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

2.  Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

Authors:  Stephen P Hunger; Xiaomin Lu; Meenakshi Devidas; Bruce M Camitta; Paul S Gaynon; Naomi J Winick; Gregory H Reaman; William L Carroll
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

3.  Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.

Authors:  Lillian Sung; Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Thomas Lehrnbecher; Alan S Gamis
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113

4.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

Authors:  Ajay Vora; Nick Goulden; Rachel Wade; Chris Mitchell; Jeremy Hancock; Rachael Hough; Clare Rowntree; Sue Richards
Journal:  Lancet Oncol       Date:  2013-02-07       Impact factor: 41.316

5.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sarah K Tasian; Tiffaney Vincent; Junior W Hall; Cecilia Sheen; Kathryn G Roberts; Alix E Seif; David M Barrett; I-Ming Chen; J Racquel Collins; Charles G Mullighan; Stephen P Hunger; Richard C Harvey; Cheryl L Willman; Jordan S Fridman; Mignon L Loh; Stephan A Grupp; David T Teachey
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113

6.  Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.

Authors:  David O'Connor; Jessica Bate; Rachel Wade; Rachel Clack; Sunita Dhir; Rachael Hough; Ajay Vora; Nick Goulden; Sujith Samarasinghe
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

7.  Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Authors:  C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

8.  Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.

Authors:  Katharine Patrick; Rachel Wade; Nicholas Goulden; Clare Rowntree; Rachael Hough; Anthony V Moorman; Christopher D Mitchell; Ajay Vora
Journal:  Br J Haematol       Date:  2014-01-15       Impact factor: 6.998

9.  Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.

Authors:  Trudy D Buitenkamp; Shai Izraeli; Martin Zimmermann; Erik Forestier; Nyla A Heerema; Marry M van den Heuvel-Eibrink; Rob Pieters; Carin M Korbijn; Lewis B Silverman; Kjeld Schmiegelow; Der-Cheng Liang; Keizo Horibe; Maurizio Arico; Andrea Biondi; Giuseppe Basso; Karin R Rabin; Martin Schrappe; Gunnar Cario; Georg Mann; Maria Morak; Renate Panzer-Grümayer; Veerle Mondelaers; Tim Lammens; Hélène Cavé; Batia Stark; Ithamar Ganmore; Anthony V Moorman; Ajay Vora; Stephen P Hunger; Ching-Hon Pui; Charles G Mullighan; Atsushi Manabe; Gabriele Escherich; Jerzy R Kowalczyk; James A Whitlock; C Michel Zwaan
Journal:  Blood       Date:  2013-11-12       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.